Biosense Webster acquires Coherex Medical


Biosense Webster has announced that it has acquired Coherex Medical, developers of the Coherex WaveCrest left atrial appendage (LAA) occlusion system.

“The Coherex WaveCrest System offers substantial benefits for patients with atrial fibrillation who are at high risk for stroke, particularly for those who are contraindicated to anticoagulants and would be unprotected from the risk of cardio embolism,” says Alex Martin, president and CEO, Coherex Medical.

The Coherex WaveCrest LAA occlusion system received CE mark accreditation in September 2013. It is not currently available for investigational use or commercial distribution in the USA.